Jpmorgan Chase & CO Prelude Therapeutics Inc Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,966 shares of PRLD stock, worth $7,755. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,966
Previous 5,860
1.81%
Holding current value
$7,755
Previous $22,000
45.45%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PRLD
# of Institutions
71Shares Held
35.7MCall Options Held
500Put Options Held
300-
Orbimed Advisors LLC San Diego, CA10.9MShares$14.2 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$13.2 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$4.9 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$2.22 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$1.43 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $47.3M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...